U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4625
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRONABINOL

SMILES

CCCCCc1cc(c2[C@]3([H])C=C(C)CC[C@@]3([H])C(C)(C)Oc2c1)O

InChI

InChIKey=CYQFCXCEBYINGO-IAGOWNOFSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

Dronabinol also known as (−)-trans-delta9-tetrahydrocannabinol is an active ingredient of cannabis. The drug was approved by FDA for the treatment of anorexia in patients with AIDS and chemotherapy-induced nausea and vomiting. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P34972
Gene ID: 1269.0
Gene Symbol: CNR2
Target Organism: Homo sapiens (Human)
3.13 nM [Ki]
Target ID: P21554|||Q5UB37
Gene ID: 1268.0
Gene Symbol: CNR1
Target Organism: Homo sapiens (Human)
5.05 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.88 ng/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1.32 ng/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.96 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15.2 ng × h/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.88 ng × h/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.16 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Other AEs: Palpitations, Tachycardia...
Other AEs:
Palpitations (2.5%)
Tachycardia (2.5%)
Photophobia (2.5%)
Vision blurred (2.5%)
Eye irritation (2.5%)
Dry mouth (40%)
Fatigue (30%)
Feeling of relaxation (5%)
Hunger (10%)
Feeling hot (5%)
Thirst (5%)
Chills (2.5%)
Upper respiratory tract infection (2.5%)
Hordeolum (2.5%)
Increased appetite (7.5%)
Polydipsia (2.5%)
Sensation of heaviness (2.5%)
Muscle spasms (2.5%)
Somnolence (37.5%)
Headache (10%)
Dizziness (5%)
Paraesthesia (2.5%)
Dysgeusia (5%)
Hypoaesthesia (2.5%)
Hypotonia (2.5%)
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Other AEs: Headache...
Other AEs:
Headache (below serious, 3 patients)
Sources:
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Other AEs: Diabetes, Concussion...
Other AEs:
Diabetes (serious, 1 patient)
Concussion (serious, 1 patient)
Nausea (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hunger 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Chills 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Eye irritation 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hordeolum 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypoaesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypotonia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Muscle spasms 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Palpitations 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Paraesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Photophobia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Polydipsia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Sensation of heaviness 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Tachycardia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Upper respiratory tract infection 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Vision blurred 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Fatigue 30%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Somnolence 37.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dry mouth 40%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dizziness 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dysgeusia 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling hot 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling of relaxation 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Thirst 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Increased appetite 7.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Headache below serious, 3 patients
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Nausea below serious, 5 patients
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Concussion serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Diabetes serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function
Page: 13.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice.
1979 May 25
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.
2001
Cannabinoid antagonists: a treatment in search of an illness.
2001 Apr
Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
2001 Apr
Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
2001 Apr
Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro.
2001 Apr 23
Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.
2001 Aug 31
Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.
2001 Feb
Urine drug screens in overdose patients do not contribute to immediate clinical management.
2001 Feb
Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.
2001 Feb
delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.
2001 Feb
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
2001 Feb
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
2001 Feb
The relative contributions of ecstasy and cannabis to cognitive impairment.
2001 Jan
[Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats].
2001 Jan
Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
2001 Jan
Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.
2001 Jan
CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum.
2001 Jan
Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
2001 Jan 19
Involvement of somatodendritic 5-HT(1A) receptors in Delta(9)-tetrahydrocannabinol-induced hypothermia in the rat.
2001 Jul-Aug
Interaction between delta-9-tetrahydrocannabinol and indomethacin.
2001 Jul-Aug
Concordance between verbal report and urine screen of recent marijuana use in adolescents.
2001 Jul-Aug
Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.
2001 Jun
Cannabinoid-induced alterations in brain disposition of drugs of abuse.
2001 Jun 1
Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets.
2001 Mar
Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.
2001 Mar
Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol.
2001 Mar
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones.
2001 Mar
Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
2001 Mar
Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV).
2001 Mar 26
Neurobiology. How cannabinoids work in the brain.
2001 Mar 30
Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
2001 May
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
2001 May
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
2001 May
Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
2001 May 11
Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.
2001 May 15
Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor.
2001 May-Jul
Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
2001 May-Jun
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
2001 Oct
Solid-phase extraction and GC-MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory.
2001 Oct
Simultaneous determination of delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry.
2001 Oct
A cannabinoid mechanism in relapse to cocaine seeking.
2001 Oct
Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users.
2001 Oct
Marijuana abstinence effects in marijuana smokers maintained in their home environment.
2001 Oct
Neuropsychological performance in long-term cannabis users.
2001 Oct
Ethanol increases plasma Delta(9)-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers.
2001 Oct 1
Differential effects of delta 9-THC on spatial reference and working memory in mice.
2001 Sep
Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat.
2001 Sep
R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.
2001 Sep 7
Hu 210: a potent tool for investigations of the cannabinoid system.
2001 Summer
Patents

Sample Use Guides

Appetite Stimulation: Initially, 2.5 mg capsules should be administered orally twice daily, before lunch and supper. For patients unable to tolerate this 5 mg/day dosage, the dosage can be reduced to 2.5 mg/day, administered as a single dose in the evening or at bedtime. Antiemetic: it is best administered at an initial dose of 5 mg/m2, given 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy is given, for a total of 4 to 6 doses/day. Should the 5 mg/m2 dose prove to be ineffective, and in the absence of significant side effects, the dose may be escalated by 2.5 mg/m2 increments to a maximum of 15 mg/m2 per dose.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
DRONABINOL
HSDB   INN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
.DELTA.1-THC
Common Name English
MARINOL
Brand Name English
QCD 84924
Code English
ABBOTT 40566
Code English
THC
Common Name English
SP 104
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM
MI  
Common Name English
TETRAHYDROCANNABINOL
Common Name English
(6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
DELTA-9-TETRAHYDROCANNABINOL
Common Name English
DELTA-9-THC
Common Name English
(6AR,10AR)-6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
ABBOTT-40566
Code English
DRONABINOL [ORANGE BOOK]
Common Name English
J882F
Code English
.DELTA.9-THC
Common Name English
QCD-84924
Code English
DRONABINOL [VANDF]
Common Name English
DRONABINOL [INN]
Common Name English
TETRAHYDROCANNABINOL, DELTA-9 TRANS
Common Name English
SP-104
Code English
.DELTA.-9-TETRAHYDROCANNABINOL
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
Common Name English
DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Common Name English
.DELTA.9-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [USAN]
Common Name English
(-)-.DELTA.1-3,4-TRANS-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [WHO-DD]
Common Name English
DRONABINOL [HSDB]
Common Name English
DRONABINOL [MART.]
Common Name English
DRONABINOL [USP MONOGRAPH]
Common Name English
NSC-134454
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM [MI]
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR-TRANS)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000008010
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 668918
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
DEA NO. 7369
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
LIVERTOX 947
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC A04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 498215
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
CFR 21 CFR 1308.35
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 652218
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 54890
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
EU-Orphan Drug EU/3/16/1621
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC N02BG10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NDF-RT N0000175782
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 628818
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-VATC QA04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 620417
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 549616
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 734820
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL465
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
RXCUI
10402
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4109
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
IUPHAR
2424
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
INN
5547
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EVMPD
SUB06407MIG
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
DRUG BANK
DB00470
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EPA CompTox
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MERCK INDEX
M10624
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TETRAHYDROCANNABINOL
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
LACTMED
Dronabinol
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
FDA UNII
7J8897W37S
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MESH
D013759
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
NCI_THESAURUS
C867
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
PUBCHEM
16078
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
CAS
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
HSDB
6471
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY